Kornimate/medical-research-clean huggingface dataset:
sleep apnea in sickle cell disease

Conditions: Sickle Cell Disease

Summary: despite the fact that obstructive sleep apnoea (osa) is highly prevalent in the sickle cell population, studies focusing on the associations of the two diseases and their common pathophysiological mechanisms are scarce. osa is one of the most common conditions responsible for hemoglobin desaturation. the nocturnal hemoglobin desaturation occurring in some sickle cell disease (scd) patients with osa could trigger hemoglobin s polymerization and red blood cell (rbc) sickling, leading to further blood rheological alterations, hence increasing the risks for voc. moreover, osa has been demonstrated to increase oxidative stress and inflammation in non sickle cell disease (scd) patients, which, in scd patients, could increase the risk for complications. finally, osa is accompanied by impaired vascular function and autonomic nervous system dysfunction in the general population. indeed, the presence of osa in scd could increase the clinical severity of patients and the frequency of voc.


Eligibility criteria:
inclusion criteria: * homozygous hbs (hemoglobin s) (ss) patients, * aged between 15 and 3 months and 50 years old, * in steady state (i.e. without vaso-occlusive crisis or recent blood transfusion), * followed by the sickle cell center of the hospices civils de lyon, * and showing symptoms of osa. exclusion criteria: * patients receiving treatment of osa, * recent blood transfusion (less than 2 months), * patients not at steady state (voc or acute chest syndrome less than 2 months), * pregnancy.

Keywords: sickle cell disease obstructive sleep apnoea vaso-occlusive crisis
china subpopulation: evaluation of efficacy and safety of belantamab mafodotin, bortezomib and dexamethasone versus daratumumab, bortezomib and dexamethasone in participants with relapsed/refractory multiple myeloma

Conditions: Multiple Myeloma

Summary: this study is designed to evaluate safety and efficacy of belantamab mafodotin in combination with bortezomib/dexamethasone versus daratumumab in combination with bortezomib/dexamethasone in the chinese participants with relapsed/refractory multiple myeloma.


Eligibility criteria:
inclusion criteria: * confirmed diagnosis of multiple myeloma as defined by the international myeloma working group (imwg) criteria. * previously treated with at least 1 prior line of multiple myeloma (mm) therapy and must have documented disease progression during or after their most recent therapy. * eastern cooperative oncology group (ecog) performance status of 0 to 2. * must have at least 1 aspect of measurable disease, defined as one of the following; 1. urine m-protein excretion \>=200 mg per 24-hour, or 2. serum m-protein concentration \>=0.5 grams per deciliter (g/dl), or 3. serum free light chain (flc) assay: involved flc level \>=10 mg per dl (\>=100 mg per liter) and an abnormal serum free light chain ratio (\ 1.65). * all prior treatment-related toxicities (defined by national cancer institute common toxicity criteria for adverse events \[nci-ctcae\] version 5.0) must be \<=grade 1 at the time of enrollment, except for alopecia. * adequate organ function exclusion criteria: * intolerant to daratumumab. * refractory to daratumumab or any other anti-cd38 therapy (defined as progressive disease during treatment with anti-cd38 therapy, or within 60 days of completing that treatment). * intolerant to bortezomib, or refractory to bortezomib (defined as progressive disease during treatment with a bortezomib-containing regimen of 1.3 mg/m\^2 twice weekly, or within 60 days of completing that treatment). note: participants with progressive disease during treatment with a weekly bortezomib regimen are allowed. * ongoing grade 2 or higher peripheral neuropathy or neuropathic pain. * prior treatment with anti-b-cell maturation antigen (anti-bcma) therapy. * prior allogenic stem cell transplant. * any serious and/or unstable pre-existing medical, psychiatric disorder or other conditions, including renal, liver, cardiovascular, or certain prior malignancies. * corneal epithelial disease

Keywords: china subpopulation belantamab mafodotin relapsed/refractory multiple myeloma daratumumab bortezomib dexamethasone multiple myeloma
feasibility study of the lvis™ (low-profile visualized intraluminal support)device

Conditions: Intracranial Aneurysms

Summary: the purpose of this study is to evaluate the safety and probable benefit of the low-profile visualized intraluminal support (lvis™ and lvis™ jr.)devices from microvention, inc. when used to facilitate endovascular coiling of unruptured wide-neck intracranial aneurysms with bare platinum embolization coils.

with the stent-assisted technique to treat wide neck intracranial aneurysms, the neurovascular stent is placed across the aneurysm neck, to act as a bridge to prevent coils from protruding into the parent artery. stenting may allow to more safely achieve a higher packing density of coils. these effects may improve the rates of complete aneurysm occlusion and enhance the durability of the coiling treatment.the lvis™ device manufactured by microvention, inc. has a braided design which may provide superior conformability and parent artery apposition, as well as a more reliable continuous and uniform neck bridging than other neurovascular stents.

Eligibility criteria:
inclusion criteria: * subject whose age is between 18 and 80 years old * subject with unruptured wide neck, saccular,intracranial aneurysm, \< 20mm maximum diameter in any plane ( wide neck defined as neck width ≥ 4mm or dome to-neck ratio \< 2). * subject's aneurysm arises from a parent vessel with a diameter of ≥ 2.5m and ≤ 4.5mm. * subject or his/her legally authorized representative understands the nature of the procedure and provides signed informed consent form. * subject is willing to return to the investigational site for the 30- day and 6-month follow-up evaluations exclusion criteria: * subject who presents with ruptured aneurysm, unless rupture occured 30 days or more prior to screening. * subject who presents with an intracranial mass or currently undergoing radiation therapy for carcinoma of the head or neck region. * subject with an international normalized ratio (inr)≥ 1.5 * subject with serum creatinine level \>2mg/dl at time of enrollment * subject with known allergies to nickel-titanium metal * subject with known allergies to aspirin, heparin, ticlopidine, or clopidogrel * subject with a life threatening allergy to contrast(unless treatment for allergy is tolerated) * subject who has a known cardiac disorder, likely to be associated with cardioembolic symptoms such as atrial fibrillation * subject with any condition which in the opinion of the treating physician would place the subject at a high risk of embolic stroke * subject who is currently participating in another clinical research study * subject who has had a previous intracranial stenting procedure associated with the target aneurysm * subject who is unable to complete the required follow-up * subject who is pregnant or breastfeeding * subject who has participated in a drug study within the last 30 days

Keywords: intracranial aneurysm wide-neck saccular endovascular treatment coil embolization stent bare platinum
rosac-rf : bipolar radiofrequency vs doxycycline in rosacea

Conditions: Rosacea

Summary: rosacea is a chronic facial disfiguring dermatosis characterized by different stages like flushing, erythema, telangiectasia and papulo-pustular lesions. recommended treatments include topical (metronidazole) and systemic (doxycycline) antibiotics with only a suspensive effect. the bipolar radiofrequency (rf) with elos system (infrared light) is a device emitting an electromagnetic current inducing an increase in temperature when applied on the skin, potentiated by infrared light. the monopolar rf has already been used in rosacea on a small number of cases with positive and prolonged results. rf with elos system has been evaluated on erythemato-telangiectasic rosacea with encouraging results. demodex folliculorum (df) is a long transparent mite which asymptomatically parasitizes pilosebaceous follicle of normal human skin sometimes responsible of inflammatory facial dermatoses. the prevalence and density of df are increased in rosacea, and df is suspected to play a role in the pathogenesis of rosacea. df is sensitive to heat, and the investigators hypothesize that radiofrequency treatment may affect the survival of the mite and should be effective to treat papulopustular rosacea.


Eligibility criteria:
inclusion criteria: * subjects must be between 18-70 years old * subjects with papulopustular rosacea graded moderate to severe (2 or 3) according to the physician global assessment, and with lesions on the cheeks. * prior stop of any topical treatment antibiotic, retinoid, corticoid or other topical treatment for rosacea at least 1 month before the start of the study * prior stop of any systemic treatment (antibiotic) two month before the start of the study and for isotretinoin at least 6 months * last laser treatment, by lamp, laser or led, at least 3 months before the start of the study * subjects must be abble to lie for more than 30 minutes * patient able to understand and sign the informed consent form * affiliation to a social security scheme exclusion criteria: * women of child bearing/reproductive potential * other skin disease or abnormality of the face which could interfere with the evaluation of the different criteria evaluated or with the realization of the rf * contraindications to radiofrequency: presence of a defibrillator or pacemaker, dental on the cheeks, dental equipment or metallic orthopedic next to the treated area, skin cancer on the face, progressive systemic disease, uncontrolled hypertension * immunosuppression by hiv (determined by examination) or treatment with immunosuppressive * tattoos or permanent makeup on the face * excessively tanned skin to sunlight, ultraviolet or with tanning creams during the last 2 weeks * subject carrying cochlear implants or open wound or in the process of healing * minor patient or under tutorship * cyanoacrylate or doxycycline allergy
a study on prevention strategies for ckd-shpt and related complications based on general vitamin d supplementation

Conditions: Chronic Kidney Disease 5D; Secondary Hyperparathyroidism Due to Renal Causes; Vitamin D Deficiency

Summary: 1. study content: this is a multicentre, double-blind, randomised controlled study to determine the optimal dose and duration of treatment for the correction of vitamin d insufficiency or deficiency in patients with ckd5d; to investigate whether vitamin d supplementation delays the increase in pth levels in this group of patients; and to investigate the effects on changes in ckd-mbd-related markers, cardiovascular complications, cognitive function in this group of patients. 2. study procedure: based on the inclusion and exclusion of the patients, the study was conducted in accordance with the following criteria 2. study procedure: eligible subjects were screened according to inclusion and exclusion criteria and randomly divided into three groups: high-dose vitamin d group, low-dose vitamin d group and control group. baseline data were collected before the intervention and each group was given different doses of regular vitamin d2 softgels or placebo and followed up. 25(oh)d, pth, blood ca, and blood p levels were measured every month; bone metabolism markers, fgf23, and blood counts, liver function, kidney function, lipids, and blood glucose were measured every 3 months; the prevalence of vascular calcification, the incidence of cardiovascular events, and changes in cognitive function scale scores were assessed 6 months after the intervention.


Eligibility criteria:
inclusion criteria: 1. age ≥ 18 years. 2. patients with chronic kidney disease stage 5d who have been on haemodialysis for 3 months or more 3. 5 ng/ml \< 25(oh)d \< 30 ng/ml (liquid phase tandem mass spectrometry). 4. 130 pg/ml \< pth \< 600 pg/ml (electrochemiluminescence method). 5. serum phosphorus \< 1.78 mmol/l. 6. good compliance with the treatment requirements formulated for the study. 7. informed consent from the subject. exclusion criteria: 1. patients who are prepped for or have undergone renal transplantation or parathyroidectomy. 2. taking vitamin d, active vitamin d or analogues and other drugs that may affect 25(oh)d levels within 3 months prior to enrolment 3. treatment affecting pth results (e.g. cenacaser, etc.) within 3 months prior to enrolment 4. serum calcium \> 2.55 mmol/l 5. patients who are pregnant or likely to become pregnant, breastfeeding or planning to become pregnant during the study period 6. known prior or concomitant serious illness or medical condition such as malignancy, human immunodeficiency virus, severe gastrointestinal or liver disease, intestinal malabsorptive disease, hepatitis or cardiovascular events that may worsen or shorten life expectancy and/or interfere with participation in the study 7. history of neurological/psychiatric disease, including psychosis or dementia, or any other reason that is unlikely to result in adherence to treatment or follow-up plans. 8. known or suspected allergy to any component of the study drug. 9. ongoing participation in other clinical studies.
far infrared radiation treatment of dementia and other mental illness

Conditions: Dementia

Summary: this trial is a preliminary study to determine the use of far infrared radiation for the treatment of dementia and other mental sickness.

dementia is the progressive decline in cognitive function due to damage or disease in the brain beyond what might be expected from normal aging. particularly affected areas include memory, attention, language, and problem solving. especially in the later stages of the condition, affected persons may be disoriented in place and in person (not knowing who they are). the prevalence of dementia is rising as the global life expectancy is rising. particularly in western countries, there is increasing concern about the economic impact that dementia will have in future, older populaces. it is a disease that is strongly associated with age; 1% of those aged 60-65, 6% of those aged 75-79, and 45% of those aged 95 or older suffer from the disease. we are postulating that the use of far infrared radiation on the central nervous system, the endocrine system and the viscera will have a positive effect on treating dementia and other neurological illnesses.

Eligibility criteria:
inclusion criteria: * persons age 2 or older, with dementia, alzheimer's, huntington's disease, parkinson's disease, down's syndrome, multiple sclerosis or stroke exclusion criteria: * persons with severe mental illness that are confined to mental hospitals etc., as defined by the usa diagnostic and statistical manual of mental disorders (dsm)

Keywords: familial dementia semantic dementia senile paranoid dementia
heart failure in adult patients with a history of congenital heart disease

Conditions: Congenital Heart Defects

Summary: in today's world of advanced surgery, children born with congenital heart disease (chd) are surviving into adulthood. however, the surgical procedures these children undergo do not cure the underlying problem and this these children develop other heart problems later in life. heart failure is the one of the most common heart problems effecting these patients. this heart failure can be seen in both lower pumping chambers of the heart, however, sometimes only one side of the heart is affected. since there are several congenital heart defects that are now seen in the adult population, an understanding of what causes heart failure in this patient population can help physicians develop better treatments for this condition. the goal of this study is to review the medical records of 350 adult patients with congenital heart disease that has developed heart failure. during this review, we plan to collect information regarding the various treatments utilized in these patients and to determine if there are any common elements regarding the development of heart failure in adult patients with chd.

in today's world of advanced surgery, children born with congenital heart disease (chd) are surviving into adulthood. however, the surgical procedures these children undergo do not cure the underlying problem and this these children develop other heart problems later in life. heart failure is the one of the most common heart problems effecting these patients. this heart failure can be seen in both lower pumping chambers of the heart, however, sometimes only one side of the heart is affected. since there are several congenital heart defects that are now seen in the adult population, an understanding of what causes heart failure in this patient population can help physicians develop better treatments for this condition. the goal of this study is to review the medical records of 350 adult patients with congenital heart disease that has developed heart failure. during this review, we plan to collect information regarding the various treatments utilized in these patients and to determine if there are any common elements regarding the development of heart failure in adult patients with chd.

Eligibility criteria:
inclusion criteria: * adults who have a history of congenital heart defects

Keywords: heart defects cardiology adults who have congenital heart defects
bivalirudin versus enoxaparin in critically ill covid-19 patients

Conditions: Acute Respiratory Failure; SARS CoV 2 Infection; Anticoagulants

Summary: coronavirus disease (covid-19) is characterized by a hypercoagulable state, sometimes difficult to be managed with heparin. bivalirudin, a member of the direct thrombin inhibitor drug class, offers potential advantages compared to heparin, including to its ability to exert its effect by directly attaching to and inhibiting freely circulating and fibrin-bound thrombin. investigators have therefore designed this pilot open-label randomized controlled trial to assess if a off-label infusion of bivalirudin may reduce thrombosis, mortality, intensive care unit (icu) length of stay and increase ventilator free days of patients admitted in icu for acute respiratory failure due to covid-19, as compared to first-line treatment with heparin.


Eligibility criteria:
inclusion criteria: * ratio between arterial partial pressure to inspired fraction of oxygen (pao2/fio2) \< 200 mmhg * age equal or greater of 18 years/old * detection of coronavirus 2019 at the nasal swab; * need for endotracheal intubation and invasive mechanical ventilation exclusion criteria: * known allergies to one of the two investigated drugs * presence of hematological diseases * pregnancy * recent (10 days) surgery * presence of active bleeding
computed tomography (ct)--an epidemiologic study in the young

Conditions: Cardiovascular Diseases; Coronary Disease; Atherosclerosis; Heart Diseases

Summary: to investigate the relationship between coronary heart disease risk factors and coronary artery calcification in middle age adults from the muscatine study. from 1992 through 1995, ultrafast computed tomography was used to measure coronary artery calcification. the study has been extended through january, 2001 in order to examine the role of electron beam computed tomography in detecting the presence and quantity of coronary artery calcification, a marker of the atherosclerotic process.

background: atherosclerotic heart disease, a major cause of mortality and morbidity in the united states, has been shown to have its origins in childhood. deposition of calcium occurring early in the atheromatous process is often observed in postmortem studies of coronary arteries and the aorta. ultrafast computed tomography (fast-ct) provides a highly sensitive, non-invasive technique for detecting the presence and quantity of coronary artery calcification (cac). the 'risk factors' for coronary artery disease have been determined by measuring levels of potential factors in middle-and older-aged adults and determining which predict atherosclerotic cardiovascular disease, including coronary artery disease (cad), peripheral vascular disease, and cerebrovascular disease. adult subjects with cac have a greater number of coronary risk factors, including higher cholesterols. in the age group of 30-39 years, 30 to 40 percent have radiographic evidence of coronary artery or aortic calcification. in the muscatine study, the investigators examined coronary risk factors in 2400 subjects during childhood (ages 9-11 years) and again in young adult life (ages 20 to 30 years). this population can now provide important information related to measures of childhood and young adult coronary risk factors predicting the development of the atherosclerotic process in adults in their fourth decade of life. design narrative: beginning in 1992, the longitudinal study used the non-invasive technique of ultrafast computed tomography to examine the relationship of known coronary risk factors measured in childhood and again in early adult life in order to correlate their association with coronary artery calcification. risk factors included lipids, lipoproteins, apolipoproteins, lipoprotein(a), apo(a) genotypes, homocyst(e)ine, and left ventricular mass. beginning in february 1996, electron beam computed tomography is used to associate risk factors with coronary artery calcification.

Eligibility criteria:
no eligibility criteria
prospective observational trial to evaluate quality of life after definitive chemoradiation in patients with anal cancer (lanacare)

Conditions: Anal Cancer; Quality of Life; Chemoradiation

Summary: observational study to evaluate longitudinal quality of life according to standardized eortc questionaires as well as functional outcome, oncological outcome and toxicity in patients treated with definitive chemoradiation for anal cancer

observational study to evaluate longitudinal quality of life according to standardized eortc questionaires as well as functional outcome, oncological outcome and toxicity in patients treated with definitive chemoradiation for anal cancer. qol will be evaluated by standardized eortc questionaires qlq c30 and qlq cr29. acute and late toxicity will be assessed according to ctcae 4.03. oncological outcome will be assessed with regard to local and distant control, patterns of recurrence, freedom from treatment failure and overall survival. correlations of physicians- and patients-assessed functional outcomes are planned.

Eligibility criteria:
inclusion criteria: * histologically proven anal cancer without distant metastases * indication for definitive chemoradiation therapy based on multidisciplinary evaluation * age \>=18 years * written informed consent * ability to answer the standardized questionaires according to the treating physician exclusion criteria: * age \< 18 years * prior systemic therapy with regard to anal cancer * distant metastases * second malignancy

Keywords: anal cancer quality of life chemoradiation